Antiretroviral therapy recommendations for the global community
Antiretroviral reduction
Increased survival among HIV-1 and HIV-2 dual-infected individuals compared to HIV-1 single-infected individuals
Soluble CD14 is independently associated with coronary calcification and extent of subclinical vascular disease in treated HIV infection
Relationship of immunologic response to antiretroviral therapy with non-AIDS defining cancer incidence
Week 48 results from a randomized clinical trial of rilpivirine/emtricitabine/tenofovir disoproxil fumarate vs. efavirenz/emtricitabine/tenofovir disoproxil fumarate in treatment-naive HIV-1-infected adults
Protective effect of hepatitis B virus-active antiretroviral therapy against primary hepatitis B virus infection
Findings in asymptomatic HIV-infected patients undergoing chest computed tomography testing
Reduced markers of HIV persistence and restricted HIV-specific immune responses after early antiretroviral therapy in children
Impact of viral load and the duration of primary infection on HIV transmission
The origin and emergence of an HIV-1 epidemic
Health literacy predicts pediatric dosing accuracy for liquid zidovudine
Earlier initiation of ART and further decline in mother-to-child HIV transmission rates, 2000–2011
Inflammatory cytokines and mortality in a cohort of HIV-infected adults with alcohol problems
The protective effect of HIV-2 infection
Persistent HIV infection in newborns
Innate immunity cell activation in virologically suppressed HIV-infected maraviroc-treated patients
Massive hypereosinophilia and vasculitis associated with major expansion of interleukin-5-producing CD8+ T cells in HIV-1 infection
Drug reaction with eosinophilia and systemic symptoms associated with raltegravir use
Reactivation of hepatitis B virus infection associated with maraviroc use in an HIV-infected patient